Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 3c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 EPS of ($0.02), $0.03 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $13.67 million versus the consensus estimate of $11.19 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• NeOnc Phase 2a brain cancer trial shows 48.9% survival vs. 20% benchmark
• Abercrombie & Fitch (ANF) PT Raised to $153 at UBS on Decent Q2, Stable Trend Across Brands